Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Replimune Group (NASDAQ: REPL) has granted inducement equity awards to 30 newly hired non-executive employees. The awards include non-qualified stock options to purchase 95,250 shares and restricted stock units (RSUs) for 158,570 shares. The December stock options have an exercise price of $13.05 per share, while January options are priced at $12.02 per share.
The stock options have a 10-year term with a four-year vesting schedule: 25% vests after one year, with the remainder vesting monthly over three years. RSUs vest in approximately four equal annual installments, beginning November 15, 2025 for December grants and February 15, 2026 for January grants. These inducement awards were approved under Nasdaq Listing Rule 5635(c)(4) and align with the terms of the company's 2018 Equity Incentive Plan.
Replimune Group (NASDAQ: REPL) ha concesso premi in azioni di incentivazione a 30 nuovi dipendenti non esecutivi. I premi includono opzioni su azioni non qualificate per l'acquisto di 95.250 azioni e unità di azioni ristrette (RSU) per 158.570 azioni. Le opzioni su azioni di dicembre hanno un prezzo di esercizio di $13.05 per azione, mentre le opzioni di gennaio hanno un prezzo di $12.02 per azione.
Le opzioni su azioni hanno una durata di 10 anni con un piano di maturazione di quattro anni: il 25% matura dopo un anno, con il resto che matura mensilmente nei tre anni successivi. Le RSU maturano in circa quattro rate annuali uguali, a partire dal 15 novembre 2025 per i premi di dicembre e dal 15 febbraio 2026 per i premi di gennaio. Questi premi di incentivazione sono stati approvati ai sensi della Regola 5635(c)(4) di Nasdaq e sono in linea con i termini del Piano di Incentivazione azionaria del 2018 della società.
Replimune Group (NASDAQ: REPL) ha otorgado incentivos en acciones a 30 nuevos empleados no ejecutivos. Los incentivos incluyen opciones sobre acciones no calificadas para comprar 95,250 acciones y unidades restringidas de acciones (RSUs) para 158,570 acciones. Las opciones de acciones de diciembre tienen un precio de ejercicio de $13.05 por acción, mientras que las opciones de enero están valoradas en $12.02 por acción.
Las opciones de acciones tienen un plazo de 10 años con un calendario de adquisición de cuatro años: el 25% se adquiere después de un año, y el resto se adquiere mensualmente durante tres años. Las RSUs se adquieren en aproximadamente cuatro cuotas anuales iguales, comenzando el 15 de noviembre de 2025 para los incentivos de diciembre y el 15 de febrero de 2026 para los incentivos de enero. Estos incentivos fueron aprobados bajo la Regla 5635(c)(4) de Nasdaq y se alinean con los términos del Plan de Incentivos en Equidad de 2018 de la compañía.
Replimune Group (NASDAQ: REPL)는 30명의 새로 고용된 비상근 직원에게 유도 주식 보상을 부여했습니다. 이 보상에는 95,250주를 구매할 수 있는 비자격 주식 옵션과 158,570주의 제한된 주식 단위(RSU)가 포함됩니다. 12월 주식 옵션의 행사 가격은 $13.05이고, 1월 옵션의 가격은 $12.02입니다.
주식 옵션은 10년의 유효 기간을 가지며 4년의 취득 일정으로 설정됩니다: 25%는 1년 후에 취득되고, 나머지는 3년 동안 매월 취득됩니다. RSU는 약 4개의 동등한 연간 분할로 취득되며, 12월 보상은 2025년 11월 15일부터, 1월 보상은 2026년 2월 15일부터 시작됩니다. 이러한 유도 보상은 Nasdaq 상장 규칙 5635(c)(4)에 따라 승인되었으며 회사의 2018년 지분 인센티브 계획의 조건과 일치합니다.
Replimune Group (NASDAQ: REPL) a accordé des récompenses en actions d'incitation à 30 nouveaux employés non exécutifs. Les récompenses comprennent des options d'actions non qualifiées pour l'achat de 95 250 actions et des unités d'actions restreintes (RSU) pour 158 570 actions. Les options d'actions de décembre ont un prix d'exercice de $13.05 par action, tandis que les options de janvier sont fixées à $12.02 par action.
Les options d'actions ont une durée de 10 ans avec un calendrier de vesting de quatre ans : 25 % sont acquises après un an, le reste étant acquis mensuellement sur trois ans. Les RSU sont acquises en environ quatre versements annuels égaux, à partir du 15 novembre 2025 pour les attributions de décembre et du 15 février 2026 pour celles de janvier. Ces récompenses d'incitation ont été approuvées en vertu de la règle d'inscription 5635(c)(4) de Nasdaq et sont conformes aux termes du plan d'incitation en actions de la société de 2018.
Replimune Group (NASDAQ: REPL) hat 30 neu eingestellten nicht-executive Mitarbeitern Anreizzahlungen in Form von Aktien gewährt. Die Zahlungen umfassen nicht qualifizierte Aktienoptionen zum Erwerb von 95.250 Aktien und eingeschränkte Aktieneinheiten (RSUs) für 158.570 Aktien. Die Dezember-Aktienoptionen haben einen Ausübungspreis von $13.05 pro Aktie, während die Januar-Optionen zu $12.02 pro Aktie bewertet sind.
Die Aktienoptionen haben eine Laufzeit von 10 Jahren mit einem vierjährigen Vesting-Zeitplan: 25% werden nach einem Jahr fällig, während der Rest in den folgenden drei Jahren monatlich fällig wird. RSUs werden in etwa vier gleichmäßige jährliche Raten fällig, beginnend am 15. November 2025 für die Dezember-Zahlungen und am 15. Februar 2026 für die Januar-Zahlungen. Diese Anreizzahlungen wurden gemäß der Nasdaq-Listing-Regel 5635(c)(4) genehmigt und stehen im Einklang mit den Bedingungen des Unternehmensplans für Eigenkapitalanreize von 2018.
- Successful recruitment of 30 new employees indicating company expansion
- Structured equity compensation plan to retain talent over long-term (4-year vesting)
- Potential dilution of existing shareholders through issuance of 253,820 new shares
WOBURN, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees.
The Company recently granted equity awards to 30 employees as a material inducement to commencing their employment with the Company. The inducement awards consist of non-qualified stock options to purchase an aggregate of 95,250 shares of the Company's common stock and restricted stock units representing an aggregate of 158,570 shares of the Company's common stock.
The non-qualified stock options consist of grants in December having an exercise price of
The aforementioned inducement awards were approved by the compensation committee of the Company's board of directors in reliance on the employment inducement exception under Nasdaq Listing Rule 5635(c)(4). While the inducement awards were granted outside of the Company’s 2018 Equity Incentive Plan, the awards will have terms and conditions consistent with those set forth under such plan.
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com
Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com
FAQ
How many shares are included in REPL's January 2025 inducement grants?
What is the exercise price for REPL's January 2025 stock options?
What is the vesting schedule for REPL's 2025 inducement RSUs?
How many new employees received REPL's inducement grants in 2025?
What is the vesting period for REPL's 2025 stock option grants?
